<DOC>
	<DOC>NCT00502060</DOC>
	<brief_summary>Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer</brief_summary>
	<brief_title>Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>tumor progressed on standard therapy or ineligible for standard therapy life expectancy of 12 weeks or more WHO performance status 02 History of active interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Phase I</keyword>
	<keyword>AZD2171</keyword>
	<keyword>ZD1839</keyword>
	<keyword>solid tumor</keyword>
</DOC>